ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
50 announcements
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma has allotted 49,112 equity shares under its ESOP Plan 2022 to eligible employees upon exercise of options. The allotment increases its paid-up share capital.
Mankind Pharma has allotted 49,112 equity shares under its ESOP scheme. This allotment increases the paid-up share capital by Rs. 49,112 in face value.
Mankind Pharma announced the cessation of Mr. Bharat Anand as an Independent Director, effective August 30, 2026, upon the completion of his second term.
Mankind Pharma's board approved the voluntary liquidation of its subsidiary, Bharat Serums and Vaccines Limited, to integrate its business into the parent company.
Mankind Pharma has received an improved ESG rating of 64 from CRISIL, categorized as 'Strong'. The rating was assigned independently without company engagement.
Mankind Pharma entered an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. The deal covers commercialisation of insulin analogues in India.
Mankind Pharma Limited has issued a Postal Ballot Notice to seek shareholder approval for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director.
Mankind Pharma has completed the realignment of security cover for its NCDs. Consequently, it has released the pledge on 28,280 shares of Bharat Serums and Vaccines.
Mankind Pharma has incorporated a wholly-owned subsidiary in the Netherlands, "Mankind Pharma (Netherlands) B.V.", with an issued capital of ₹55.06 Crore.
Mankind Pharma has incorporated a wholly-owned subsidiary, 'Mankind Pharma (Netherlands) B.V.', in the Netherlands as previously disclosed.
Mankind Pharma has appointed Mr. Anish Vanraj Bafna as an Additional Director (Non-Executive Independent Director), effective August 10, 2026.
Mankind Pharma held its 35th Annual General Meeting on August 4, 2026. The meeting covered routine business, including the adoption of financial statements and director re-appointments.
Mankind Pharma's FY25 ESG report highlights a 73% carbon reduction since FY21 and 63% renewable energy mix. The company is focused on embedding sustainable practices across manufacturing and its value chain.
Mankind Pharma approved a ₹150 Crore corporate guarantee in favour of banks for Bharat Serums and Vaccines Limited's credit facilities. This contingent liability supports BSV's operations.
Mankind Pharma reported Q1 FY27 revenue of ₹4,031 crore, up 12.9% YoY. EBITDA grew 24.7% to ₹1,060 crore, with a margin of 26.3%.
Mankind Pharma reported strong Q1 FY27 results with 12.9% revenue growth and 29.1% PAT growth. Strategy focuses on chronic segment expansion, BSV integration, and OTC growth.
Mankind Pharma Ltd reported revenue from operations of ₹4,031 Cr (+12.9% YoY) and net profit of ₹574.1 Cr (+29.1% YoY) for Q1 FY27.
Mankind Pharma has completed the sale of its 100% stake in Broadway Hospitality Services Private Limited for a cash consideration of ₹ 49 Crore.
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) with the exchange. This is a standard periodic disclosure of the company's ownership structure.
Mankind Pharma will hold a board meeting on July 30, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Mankind Pharma will sell its subsidiary Broadway Hospitality Services to AKRK Projects for ₹49 Crore. The cash deal is expected to conclude by October 2026.
Mankind Pharma will incorporate a wholly-owned subsidiary in Netherlands with a 54 Crore investment. The entity will hold R&D assets and pursue niche therapy joint ventures.
Mankind Pharma approved divesting 100% stake in Broadway Hospitality for Rs. 49 Crore. It also plans to invest €5 Million to incorporate a new Netherlands-based subsidiary.
Mankind Pharma Limited submitted its Business Responsibility & Sustainability Report for FY 2025-26. The report details the company's environmental, social, and governance performance metrics.
Mankind Pharma has scheduled its 35th AGM for August 4, 2026, via video conferencing. The company also released its Annual Report for FY 2025-26.
Mankind Pharma Ltd will hold its 35th Annual General Meeting on August 4, 2026 via video conference. Notice and the annual report will be sent to members.
Mankind Pharma appointed Nilesh Kulkarni as Head of HR and Senior Management Personnel. Prateek Dubey transitions to new responsibilities, effective June 8, 2026, amid organizational restructuring.